InsiderDB

Lobbying disclosures · Lobbying report

ALNY: second_quarter 2026 lobbying report

General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.

Follow ALNY
Became public
Jul 5, 2026, 5:51 AM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 3:19 PM EST

Why this is connected

Exact legal-name match: ALNYLAM PHARMACEUTICALS, INC. (https://www.sec.gov/Archives/edgar/data/1178670/).

Reported lobbying amounts

Income: $50,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/f02c0297-08b3-41ab-9814-c6fca8d43ed8/","filing_uuid":"f02c0297-08b3-41ab-9814-c6fca8d43ed8","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/f02c0297-08b3-41ab-9814-c6fca8d43ed8/print/","filing_document_content_type":"text/html","income":"50000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-07-05T05:51:05-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2231 48th Street NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20007","registrant":{"id":401108183,"url":"https://lda.gov/api/v1/registrants/401108183/","house_registrant_id":56368,"name":"LMH STRATEGIC SOLUTIONS","description":null,"address_1":"2231 48th Street NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20007","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ALANNA TEMME","contact_telephone":"+1 202-503-5189","dt_updated":"2026-07-09T12:14:41.865548-04:00"},"client":{"id":64726,"url":"https://lda.gov/api/v1/clients/64726/","client_id":64726,"name":"ALNYLAM PHARMACEUTICALS, INC.","general_description":"Pharmaceutical manufacturer.","client_government_entity":null,"client_self_select":false,"state":"MA","state_display":"Massachusetts","country":"US","country_display":"United States of America","ppb_state":"MA","ppb_state_display":"Massachusetts","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-02-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"General Medicare and Medicaid Issues. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.946/S.1862: ORPHAN Cures Act. Pediatric Review Reauthorization.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145804,"prefix":null,"prefix_display":null,"first_name":"ALANNA","nickname":null,"middle_name":null,"last_name":"TEMME","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, U.S. Representative Jon Porter","new":false},{"lobbyist":{"id":149520,"prefix":null,"prefix_display":null,"first_name":"SONIA","nickname":null,"middle_name":null,"last_name":"GOH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":153409,"prefix":null,"prefix_display":null,"first_name":"SOPHIE","nickname":null,"middle_name":null,"last_name":"KHANAHMADI","suffix":null,"suffix_display":null},"covered_position":"Legislative Asst., Rep. Martha Roby; Legislative Asst., Rep. Lee Terry; Staff Asst./LC, Senator Jeff Sessions","new":false}],"government_entities":[{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+5.41% ALNY

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in ALNY

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.